首页 › 基金 › Affinity Asset Advisors, LLC › TVTX
Affinity Asset Advisors, LLC 对 TVTX 的持仓历史
TRAVERE THERAPEUTICS INC · 医疗保健
Affinity Asset Advisors, LLC 在 Q3 2026 的 13F 申报中披露持有 TVTX(TRAVERE THERAPEUTICS INC)300,000 股,市值约 US$17.7M,约占其申报组合的 0.82%,在其申报持仓中市值排名第 33 位。 Affinity Asset Advisors, LLC 最近 13 个申报季度中有 11 个季度披露了 TVTX 持仓,最早可追溯至 Q3 2023。
最后更新: 2026-11-14 · 来源: SEC EDGAR Form 13F-HR
Affinity Asset Advisors, LLC 对 TVTX 的持仓演变
Affinity Asset Advisors, LLC 于 Q3 2023 首次披露 TVTX 持仓:100,000 股(约 US$894K)。 该持仓在 Q3 2026 达到峰值 300,000 股,市值约 US$17.7M。 在 11 次申报中,Affinity Asset Advisors, LLC 1 次增持、2 次减持、5 次保持不变。 最近一期申报(Q3 2026)显示持股 300,000 股、市值约 US$17.7M。 持仓曾出现大幅变动:Q4 2024 减持约 96% (随后一个季度股价上涨 3%)、Q1 2025 增持约 3400% (随后一个季度股价下跌 17%)、Q1 2026 减持约 96% (随后一个季度股价上涨 91%)。
逐季持仓明细
| 季度 | 股数 | 金额 | 变化 |
|---|---|---|---|
| Q3 2023 | 100.00K | $894.00K | 新进 |
| Q1 2024 | 125.00K | $963.75K | 新进 |
| Q3 2024 | 5.00M | $4.32M | 新进 |
| Q4 2024 | 200.00K | $3.48M | 减持 |
| Q1 2025 | 7.00M | $6.99M | 增持 |
| Q2 2025 | 7.00M | $6.69M | 持有 |
| Q3 2025 | 7.00M | $7.93M | 持有 |
| Q4 2025 | 7.00M | $9.99M | 持有 |
| Q1 2026 | 300.00K | $8.91M | 减持 |
| Q2 2026 | 300.00K | $17.04M | 持有 |
| Q3 2026 | 300.00K | $17.66M | 持有 |
折线上的点按变动类型着色;缺失季度表示该季未申报持仓。
关于 TVTX 与 13F 数据
TVTX(TRAVERE THERAPEUTICS INC)属于医疗保健行业。我们追踪的基金中还有 57 只申报持有 TVTX,申报仓位最大的包括:PERCEPTIVE ADVISORS LLC (US$213.2M), Rock Springs Capital Management LP (US$123.8M), Kynam Capital Management, LP (US$113.6M)。 根据美国 SEC 规定,管理资产超过 1 亿美元的机构投资者须在每季度结束后 45 天内提交 13F 表,披露其美股多头持仓。该数据不包含空头、大部分期权及海外持仓,因此应将其视为季度快照而非实时仓位。
其它持有 TVTX 的基金
- PERCEPTIVE ADVISORS LLC 3.75M 股 · $213.18M · Q2 2026
- Rock Springs Capital Management LP 2.18M 股 · $123.79M · Q2 2026
- Kynam Capital Management, LP 2.00M 股 · $113.62M · Q2 2026
- Stephens Investment Management Group LLC 1.88M 股 · $110.50M · Q3 2026
- EMERALD ADVISERS, LLC 1.56M 股 · $92.06M · Q3 2026
- Context Capital Management, LLC 62.70M 股 · $73.14M · Q3 2026
- MPM BioImpact LLC 1.12M 股 · $63.78M · Q2 2026
- EMERALD MUTUAL FUND ADVISERS TRUST 984.85K 股 · $57.99M · Q3 2026
- Jones Hill Capital LP 959.63K 股 · $56.50M · Q3 2026
- Eversept Partners, LP 798.97K 股 · $45.39M · Q2 2026
- Polar Asset Management Partners Inc. 30.50M 股 · $35.91M · Q2 2026
- TENOR CAPITAL MANAGEMENT Co., L.P. 28.00M 股 · $32.96M · Q2 2026
更多关于 Affinity Asset Advisors, LLC
常见问题
How long has Affinity Asset Advisors, LLC held TVTX?
Affinity Asset Advisors, LLC has disclosed TVTX holdings in 11 of the last 13 reported quarters, going back to Q3 2023.
What is Affinity Asset Advisors, LLC's current position in TVTX?
As of Q3 2026, Affinity Asset Advisors, LLC holds 300.00K shares of TVTX (TRAVERE THERAPEUTICS INC), valued at $17.66M, representing 0.82% of its reported portfolio and ranking #33.
Has Affinity Asset Advisors, LLC been buying or selling TVTX?
In the latest 13F filing (Q3 2026), Affinity Asset Advisors, LLC held unchanged its position in TVTX. The position peaked in Q3 2026 at 300.00K shares.
Which other funds hold TVTX?
Other major institutional holders of TVTX include PERCEPTIVE ADVISORS LLC, Rock Springs Capital Management LP, Kynam Capital Management, LP, among 57 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.